17. November 2009 07:55
YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.
[More]
42bfd64b-9327-4a28-ab0e-65e72d62bd06|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Analgesia, Angiogenesis, Antibody, Biotechnology, Cancer, Cisplatin, Dermatitis, Fentanyl, Immunology, Liposome, Monoclonal Antibody, Opioids, Xenograft
17. November 2009 03:30
ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.
[More]
16. November 2009 10:40
Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.
[More]
c39fca64-5a76-4779-9918-3fae4e22b2af|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antibody, Autoimmune Disease, Biotechnology, Brentuximab Vedotin, Cancer, Cell, Genetics, Glioblastoma, Kidney Cancer, Lymphoma, Monoclonal Antibody, Multiple Myeloma, Oncology, Renal Cell Carcinoma
16. November 2009 09:21
The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
[More]
f2838858-9c45-4eb8-a649-a6b5654e9bab|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Acne, Antibody, Cancer, Cell, Cetuximab, Chemotherapy, Colorectal Cancer, Endocrinology, Fertility, Glioblastoma, Head and Neck Cancer, Hypersensitivity, Infertility, Irinotecan, Liposome, Lung Cancer, Metformin, Monoclonal Antibody, Multiple Sclerosis, Non-Small Cell Lung Cancer, Oncology, Oxaliplatin, Radiotherapy, Small Cell Lung Cancer, Smoking, Squamous Cell Carcinoma, Vaccine
13. November 2009 03:00
Health Robotics today announced that Innomed/BioRobotics, on the heels of its prior market success with Oncology Surgery robots, has exclusively selected Health Robotics' CytoCare(TM) Robot to reach its objective to become the gold standard for Oncology Robotics IV Admixtures in the Republic of Korea and synergistically provide an end-to-end Cancer Robotics solution.
[More]
12. November 2009 07:57
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.
[More]
404e795a-2a65-4cf8-a836-c001cbc85a35|0|.0
Posted in: Business / Finance | Pharmaceutical News
Tags: Antibody, Biotechnology, Cancer, Cell, Chemotherapy, Folic Acid, Hodgkin's Lymphoma, Hospital, Hypoxia, Lymphoma, Methotrexate, Monoclonal Antibody, Non-Hodgkin's Lymphoma, Oncology, Osteosarcoma, Rituximab, Yttrium, Zevalin
11. November 2009 01:30
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
[More]
78fc2450-35aa-40d5-83a7-3f877d32837c|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Alzheimer's Disease, Anthrax, Antibody, Brain, Cold Sores, Depression, Monoclonal Antibody, Multiple Sclerosis, Nervous System, Neurology, Neuron, Parkinson's Disease, Stroke, Traumatic Brain Injury
10. November 2009 07:56
Bristol-Myers Squibb Company and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.
[More]
cd62c559-1b13-404b-b80e-ee2576fff949|1|5.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antibody, Anti-Inflammatory, Arthritis, Bone, Cancer, Education, Genetics, Immunology, Inflammatory Disease, Interleukin-6, Investment, Monoclonal Antibody, Rheumatoid Arthritis, Rheumatology
9. November 2009 08:37
Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.
[More]
8a4f0f63-da2c-44b2-b601-4247c09e9849|0|.0
Posted in: Business / Finance
Tags: Abdominal Pain, Antibody, Cancer, Constipation, Diarrhea, Hepatitis C, Monoclonal Antibody, Nausea, Oncology, Orthopedic, Palliative Care, Prostate Cancer, Virus
5. November 2009 23:50
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
[More]
acf1eb1a-43b4-45ef-8d7d-46a881a29daf|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antibody, Arthritis, Biotechnology, Cancer, Cell, Chemotherapy, Colorectal Cancer, Diarrhea, Irinotecan, Kidney Disease, Monoclonal Antibody, Oncology, Oxaliplatin, Rheumatoid Arthritis, Vectibix
5. November 2009 08:19
ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.
[More]
5. November 2009 07:59
Less restrictive dietary options, better detection, targeted avoidance measures, educational directives and potential new therapies are improving food allergy management and giving hope to the more than 12 million Americans affected according to experts at the thirteenth international food allergy conference held during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.
[More]
0da3665e-a8c6-4fc3-b932-ddd0a6c5cfd5|0|.0
Posted in: Miscellaneous News
Tags: Allergy, Antibody, Asthma, Breastfeeding, Calcium, Chinese Herbal Medicine, Diet, Education, Hospital, Immunology, Immunotherapy, Monoclonal Antibody, Nutrition, Peanut Allergy, Pediatrics
5. November 2009 07:42
Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.
[More]
c226b105-0c72-453d-ba26-10dd76b785b1|0|.0
Posted in: Business / Finance
Tags: Antibody, Biotechnology, Bipolar Disorder, Depression, Friedreich's Ataxia, Gene Expression, Investment, Monoclonal Antibody, Muscular Atrophy, Neuron, Pancreatitis, Spinal Muscular Atrophy
4. November 2009 08:33
EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.
[More]
87187116-9d64-430b-a4b3-d13382466c33|0|.0
Posted in: Medical Science News | Medical Condition News
Tags: Antibiotic, Antibody, Asparaginase, Biopsy, Brachytherapy, Bupivacaine, Calcium, Cancer, Chemotherapy, Collagen, Hospital, Monoclonal Antibody, Oncology, Prostate Cancer, Radiology, Skin Cancer, Urethra, Urology
4. November 2009 04:18
ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.
[More]
38fd0fb4-bd4d-4ee9-902f-7c8e2ef872d6|0|.0
Posted in: Business / Finance | Drug Trial News
Tags: Antibody, Biotechnology, Cancer, Diabetes, Diabetic Macular Edema, Diabetic Retinopathy, Edema, Exercise, Monoclonal Antibody, Orthopedic, Prophylaxis, Thrombosis
Subscribe